Global Extended Release Drug Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Extended Release Drug Market Research Report 2024
Drug delivery systems are engineered technologies for controlled release of drugs or to the targeted delivery of drugs. Drug delivery system is a kind of formulation that enables the administration of therapeutic agents in the body and improves its safety and efficacy by controlling the time, rate and place of drug release in the body. Most of the conventional oral products of drugs are formulated to release the active ingredient as soon as it is administered. Now the pattern has been changed to modified release dosage forms to achieve better therapeutic target. Extended release drugs is a type of dosage forms which allows a two-fold reduction in frequency of dosage administered in the body.
According to MRAResearch’s new survey, global Extended Release Drug market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Extended Release Drug market research.
Key companies engaged in the Extended Release Drug industry include Pfizer, Mallinckrodt, Teva, Johnson & Johnson, Endo Pharmaceuticals, Purdue Pharma, Mylan, Hisamitsu Pharmaceutical and Sun Pharmaceutical Industries, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Extended Release Drug were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Extended Release Drug market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Extended Release Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
Mallinckrodt
Teva
Johnson & Johnson
Endo Pharmaceuticals
Purdue Pharma
Mylan
Hisamitsu Pharmaceutical
Sun Pharmaceutical Industries
Segment by Type
Sustained Release Drug
Controlled Release Drug
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Extended Release Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Extended Release Drug market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Extended Release Drug market research.
Key companies engaged in the Extended Release Drug industry include Pfizer, Mallinckrodt, Teva, Johnson & Johnson, Endo Pharmaceuticals, Purdue Pharma, Mylan, Hisamitsu Pharmaceutical and Sun Pharmaceutical Industries, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Extended Release Drug were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Extended Release Drug market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Extended Release Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Mallinckrodt
Teva
Johnson & Johnson
Endo Pharmaceuticals
Purdue Pharma
Mylan
Hisamitsu Pharmaceutical
Sun Pharmaceutical Industries
Segment by Type
Sustained Release Drug
Controlled Release Drug
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Extended Release Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source